+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Interferons Global Market Report 2020-30: COVID-19 Implications and Growth

  • ID: 5017378
  • Report
  • April 2020
  • Region: Global
  • 200 pages
  • The Business Research Company

FEATURED COMPANIES

  • 3Sbio
  • Bayer AG
  • Biosidus
  • Merck
  • Novartis AG
  • PROBIOMED
Interferons Market Global Report 2020: COVID-19 Implications and Growth from the publisher covers this critical market and the impact on it from the COVID-19 virus. It provides strategists, marketers and senior management with the critical information they need to assess the increasing demand for interferons which play a critical role in the treatment of patients with COVID-19.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 20+ geographies.
  • Understand how the market is experiencing rapid growth due to the coronavirus and how it is likely to stabilize as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3 working days of order.
Description:

Where is the largest and fastest growing market for the interferons? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Interferons market global report from the publisher answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider interferons market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The interferons market section of the report gives context. It compares the interferons market with other segments of the interferons market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, interferons indicators comparison.
Scope

Markets Covered: 1) By Type: Inteferon Alpha; Inteferon Beta; Inteferon Gamma; 2) By Application: Hepatitis B; Hepatitis C; Melanoma; Leukemia; Multiple Sclerosis; Renal Cell Carcinoma

Companies Mentioned: Roche; Merck; Bristol-Myers Squibb; Biogen Inc; Bayer AG

Countries: Brazil; China; France; Germany; India; Indonesia; Japan; South Korea; Russia; UK; USA and Australia

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, per capita expenditure.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3Sbio
  • Bayer AG
  • Biosidus
  • Merck
  • Novartis AG
  • PROBIOMED
1. Executive Summary

2. Interferons Market Characteristics

3. Interferons Market Size and Growth
3.1. Global Interferons Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Interferons Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Interferons Market Segmentation
4.1. Global Interferons Market, Segmentation by Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Inteferon Alpha
  • Inteferon Beta
  • Inteferon Gamma
4.2. Global Interferons Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Hepatitis B
  • Hepatitis C
  • Melanoma
  • Leukemia
  • Multiple Sclerosis
  • Renal Cell Carcinoma
5. Interferons Market Regional and Country Analysis
5.1. Global Interferons Market, Split by Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Interferons Market, Split by Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

6. Asia-Pacific Interferons Market
6.1. Asia-Pacific Interferons Market Overview
6.2. Asia-Pacific Interferons Market, Segmentation by Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

7. China Interferons Market
7.1. China Interferons Market Overview
7.2. China Interferons Market, Segmentation by Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

8. India Interferons Market
8.1. India Interferons Market Overview
8.2. India Interferons Market, Segmentation by Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

9. Japan Interferons Market
9.1. Japan Interferons Market Overview
9.2. Japan Interferons Market, Segmentation by Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

10. Australia Interferons Market
10.1. Australia Interferons Market, Segmentation by Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

11. Indonesia Interferons Market
11.1. Indonesia Interferons Market, Segmentation by Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

12. South Korea Interferons Market
12.1. South Korea Interferons Market, Segmentation by Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

13. Western Europe Interferons Market
13.1. Western Europe Interferons Market Overview
13.2. Western Europe Interferons Market, Segmentation by Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

14. UK Interferons Market
14.1. UK Interferons Market Overview
14.2. UK Interferons Market, Segmentation by Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

15. Germany Interferons Market
15.1. Germany Interferons Market, Segmentation by Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

16. France Interferons Market
16.1. France Interferons Market, Segmentation by Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

17. Eastern Europe Interferons Market
17.1. Eastern Europe Interferons Market Overview
17.2. Eastern Europe Interferons Market, Segmentation by Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

18. Russia Interferons Market
18.1. Russia Interferons Market, Segmentation by Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

19. North America Interferons Market
19.1. North America Interferons Market Overview
19.2. North America Interferons Market, Segmentation by Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

20. USA Interferons Market
20.1. USA Interferons Market Overview
20.2. USA Interferons Market, Segmentation by Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

21. South America Interferons Market
21.1. South America Interferons Market Overview
21.2. South America Interferons Market, Segmentation by Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

22. Brazil Interferons Market
22.1. Brazil Interferons Market, Segmentation by Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

23. Middle East Interferons Market
23.1. Middle East Interferons Market Overview
23.2. Middle East Interferons Market, Segmentation by Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

24. Africa Interferons Market
24.1. Africa Interferons Market Overview
24.2. Africa Interferons Market, Segmentation by Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

25. Interferons Market Competitive Landscape and Company Profiles
25.1. Interferons Market Competitive Landscape
25.2. Interferons Market Company Profiles
25.2.1. Roche
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. Merck
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Bristol-Myers Squibb
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. Biogen Inc
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. Bayer AG
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers and Acquisitions In The Interferons Market

27. Interferons Market Trends and Strategies

28. Interferons Market Future Outlook and Potential Analysis

29. Appendix
29.1. Abbreviations
29.2. Currencies
29.3. Research Inquiries
29.4. About the Publisher
29.5. Copyright and Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3Sbio
  • Bayer AG
  • Biosidus
  • Merck
  • Novartis AG
  • PROBIOMED
Major players in the interferons market are Roche, Merck, Bristol-Myers Squibb, Biogen Inc, Bayer AG, Zydus Cadila, Novartis AG, Pfizer Inc, Biosidus, and Nanogen.

The global interferons market is expected to grow from $6.9 billion in 2019 to about $7.5 billion in 2020 due to an increase in demand for the use of interferons along with antiretrovirals and anti-malerial drugs in the treatment of Covid-19 patients. The market is expected to stabilize and reach $8.1 billion at a CAGR of 4% through 2023.

The pandemic outbreak of corona virus is expected to drive the growth of interferons market. This is because of the ongoing trials on various drug candidates including interferons as potential therapeutic options for covid-19 treatment. Interferon-beta (IFN-beta) is a naturally occurring protein that controls the body’s antiviral responses. The drug regulators including the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA) have approved the initiation of trials evaluating interferons. For example, SNG001 which is an inhalation formulation of interferon-beta-1a that is delivered to the lungs directly via nebulization.

The interferons market consists of sales of interferons, the biopharmaceuticals that are produced using living organisms, such as microorganisms and animal cells, and have a high-therapeutic value. The market consists of revenues generated by the establishments by the sales of various types of interferons such as alpha interferons, beta interferons and gamma interferons.

North America was the largest region in the interferons market in 2019.

The development of interferons involves high R&D costs. The development of interferons is costlier than developing small molecules which are chemically synthesized, involves high operating costs, and requires a greater capital investment. This is because biologic drugs are more complex than small molecules and involve complex manufacturing processes. Additionally, manufacturers have to submit more data to demonstrate the efficacy and safety of these biologics in pre-clinical and clinical studies for successful registration. This makes the registration of biologics a costly and time-consuming process which is restraining the market growth. Due to the high R&D costs, and lengthy testing and manufacturing process, the marketed drugs would be priced much higher than the actual manufacturing costs, and this factor is likely to challenge the market growth.

Bayer and Curadev Pvt. Ltd., a drug discovery company based in India, have announced a research collaboration and license agreement for Curadev’s Stimulator of Interferon Genes (STING) antagonist program. The objective of this collaboration between Bayer and Curadev is to discover new drug candidates for the treatment of lung diseases, cardiovascular diseases and other inflammatory diseases. STING antagonists have huge potential for new treatments as STING is known to help in activating the innate immune system in auto-inflammatory diseases.

Biologics therapy is expensive and it places a substantial financial burden on the healthcare system. Increasing prevalence of diseases such as hepatitis, MS, and cancers in the world presented an opportunity to evaluate the clinical applications of biosimilars and have stimulated some of the local pharmaceutical companies to produce interferon biosimilar medications to compete (or replace) the original expensive brands. IFNs were initially investigated for their potential as antivirals, however, they are now commonly used in anti-HBV (hepatitis B virus) and anti-HCV (hepatitis C virus) therapy. The therapeutic potential of interferon biosimilars for hepatitis and cancer, coupled with the ongoing studies on interferon biosimilars to have prophylactic or therapeutic effectiveness in SARS (severe acute respiratory syndrome), influenza or another virus pandemic, is contributing to the increasing adoption of interferon biosimilars over expensive biologics.

Global interferon drugs market is projected to grow at a rapid pace in the next few years due to the increasing incidence of chronic diseases such as hepatitis-B, hepatitis-C, cancer and multiple sclerosis, the use of interferons in combinational therapies, and advent of novel drug delivery systems. Various types of interferon (IFN) have been used to treat these diseases and an important development in treating some of these diseases was the recognition that the clinical effects of IFN drug could be greatly enhanced by combining it with other drugs. For instance, IFN-α (interferon-alpha) in combination with ribavirin and polyethylene glycol molecule has shown significant improvements in virological response and without any adverse effects. However, due to the poor stability of interferon-alpha in the gastrointestinal tract, only parenteral administration ensures bioavailability, which is associated with severe side effects. Studies showed that nanoencapsulation of IFN-α within nanoparticles would improve the oral bioavailability of this drug. The use of interferons in combinational therapies, and advent of novel drug delivery systems is therefore expected to drive the market for interferons. Interferons are also being tested for their use in the treatment of COVID-19.
Note: Product cover images may vary from those shown
  • Roche
  • Merck
  • Bristol-Myers Squibb
  • Biogen Inc
  • Bayer AG
  • Zydus Cadila
  • Novartis AG
  • Pfizer Inc
  • Biosidus
  • Nanogen
  • Amega Biotech
  • Rhein Minapharm Biogenetics
  • PROBIOMED
  • Schering-Plough Corporation.
  • 3Sbio
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll